{"filings":[{"id":1251556,"accession_number":"0001193125-26-281246","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2026-06-24T21:02:19+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"CalciMedica raises ~$15M in private placement; FDA clears continued Auxora development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 18.7M units at $0.8033 each; gross proceeds ~$15M, up to $34M additional from warrant exercises.","FDA reviewed KOURAGE trial protocol amendment and interim safety data; no comments or questions, dosing may resume.","Insiders including CEO, CBO, CMO, and major holders purchase ~6.9M units.","Plans Phase 1b study of Auxora in pulmonary arterial hypertension (PAH) with data expected mid-2027.","IND clearance for oral CM5480 anticipated mid-2027; cash runway into second half of 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1231276,"accession_number":"0001193125-26-280223","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2026-06-24T10:50:38+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"CalciMedica amends loan with Avenue: extends maturity to 2029, ups convertible amount to $3M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan principal $10M unchanged; interest-only extended to Sep 2027, maturity to Sep 2029.","Lender's conversion option increased from $1M to $3M at $1.00/share; new 1M-share warrant issued at same price.","Company granted monthly Put Option to force conversion up to 20% of 15-day avg volume if VWAP >1.5x conversion price.","Existing warrant exercise price reduced from $2.32 to $1.00; beneficial ownership cap set at 4.99% (expandable to 19.99%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22250,"accession_number":"0001193125-26-218134","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2026-05-12T11:00:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica reports Q1 net income $5.0M; FDA feedback on Auxora pivotal program expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $5.0M ($0.31 basic) vs net loss $5.0M a year ago; cash $8.2M as of March 31, 2026.","R&D expenses $3.5M, G&A $2.1M; other income $10.6M from fair value adjustments on warrants and note.","FDA feedback on pivotal program design for Auxora in acute pancreatitis expected in Q2 2026.","IND submission for oral CRAC inhibitor CM5480 in pulmonary hypertension anticipated in 2027.","Phase 2b CARPO results published: Auxora showed 100% reduction in new-onset severe respiratory failure (p<0.05)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105164,"accession_number":"0001193125-26-114096","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"CalciMedica receives Nasdaq delisting notices for MVLS and bid price deficiencies","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified CalciMedica on Mar 13, 2026 that MVLS was below $35M for 30 consecutive business days.","Second notice on Mar 16, 2026 for bid price <$1.00 per share for 30 consecutive business days.","Company has until Sep 9, 2026 (MVLS) and Sep 14, 2026 (bid price) to regain compliance.","To regain compliance, stock must close at $35M+ for 10 consecutive days (MVLS) or $1.00+ for 10 days (bid price).","Company says no immediate effect on listing; considering options including reverse stock split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105163,"accession_number":"0001193125-26-086658","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica reports 2025 net loss $29.6M; cash $13M; KOURAGE safety review finds no drug toxicity","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.6M ($1.97/share) vs $13.7M ($1.22/share) in 2024; R&D expense $15.2M, G&A $7.9M.","Cash, equivalents & short-term investments $13.0M as of Dec 31, 2025; expected to fund operations into Q4 2026.","KOURAGE trial in AKI discontinued; internal & external safety review found no evidence of drug-related toxicity.","Pivotal program design for Auxora in acute pancreatitis expected 1H 2026 following constructive FDA engagement.","CM5480 for PAH: IND submission anticipated in 2027; preclinical data published in JCI Insight."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105162,"accession_number":"0001193125-26-027462","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CalciMedica discontinues Phase 2 KOURAGE trial, extends cash runway to Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 KOURAGE trial discontinued following IDMC recommendation.","Cash runway guidance updated: existing cash, equivalents, and short-term investments expected to fund operations into Q4 2026.","Previously disclosed guidance expected funding into second half of 2026.","No specific financial amounts or trial data disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105161,"accession_number":"0001193125-26-025649","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CalciMedica discontinues Phase 2 KOURAGE trial of Auxora in AKI after IDMC safety concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDMC identified a safety concern requiring re-evaluation of study design, particularly enrollment criteria.","No treatment-related deaths or SAEs requiring expedited FDA reporting in the trial.","Company plans comprehensive review of unblinded data to inform possible future AKI trials.","CEO reaffirms optimism for Auxora in acute pancreatitis; pivotal trial design expected H1 2026.","Also advancing second CRAC inhibitor CM5480 for pulmonary arterial hypertension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121420,"accession_number":"0001193125-25-275888","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica Q3 net loss $7.8M ($0.52/shr); cash $14.1M, funds into 2H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.8M ($0.52 per share), up from $5.6M ($0.50) a year ago.","Cash, equivalents, and short-term investments at $14.1M; expected to fund operations into 2H 2026.","Phase 2 KOURAGE trial in AKI with respiratory failure enrollment ongoing; data expected 1H 2026.","Positive FDA discussions on acute pancreatitis pivotal trial; final design expected 1H 2026.","Collaboration with Telperian to leverage AI analytics for pivotal trial design."],"consensus_eps_estimate":-0.4208,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121419,"accession_number":"0001193125-25-269526","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CalciMedica increases ATM facility maximum from $4.45M to $9.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price under ATM raised from $4.45M to $9.7M via prospectus supplement filed Nov 6, 2025.","Agreement with H.C. Wainwright dated Aug 11, 2023; prior supplement filed Dec 20, 2024.","Proceeds for general corporate purposes; potential dilution from additional share issuance under ATM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138082,"accession_number":"0000950170-25-106918","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica Q2 net loss $6.0M ($0.40/sh); cash $18.0M; KOURAGE trial data expected early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.0M, or $0.40 per share, vs $4.0M ($0.36) in Q2 2024.","Cash and investments $18.0M; expected to fund operations into mid-2026.","R&D expenses $4.1M, G&A $2.6M; other income fell to $0.7M from $2.6M.","Enrollment ongoing in Phase 2 KOURAGE trial for AKI with respiratory failure; 150 patients planned.","Initial FDA meeting on Auxora for acute pancreatitis constructive; pivotal trial alignment expected end-2025."],"consensus_eps_estimate":-0.357,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155495,"accession_number":"0001193125-25-151234","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve amendment to CalciMedica 2023 equity plan, adding 600,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected all three Class I director nominees: Leheny, Roberts, Guerard with over 9.5M votes each.","Ratification of Baker Tilly as independent auditor for FY 2025 passed with 12.3M votes for, 135K against.","Amendment to 2023 Equity Incentive Plan approved (8.9M for, 923K against), increasing authorized shares by 600,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155494,"accession_number":"0001193125-25-136297","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CalciMedica changes auditor to Baker Tilly after Moss Adams merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Moss Adams resigned as auditor on June 3, 2025, after merging with Baker Tilly US, LLP.","Audit Committee appointed Baker Tilly as successor independent registered public accounting firm, effective June 3, 2025.","Moss Adams' audit report for FY 2024 contained no adverse opinion or qualification; no disagreements or reportable events in 2024, 2023, or interim period through June 3, 2025.","Moss Adams furnished a letter to the SEC agreeing with the company's statements, filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155493,"accession_number":"0000950170-25-070910","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica Q1 2025 net loss $5.9M; cash $24.6M; KOURAGE trial data due end of 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.9M in Q1 2025 vs. net income of $0.1M in Q1 2024; R&D expenses rose to $4.2M.","Cash, cash equivalents and short-term investments of $24.6M; runway expected into mid-2026.","Phase 2 KOURAGE trial (AKI + respiratory failure) enrollment ongoing; data expected around end of 2025.","Post-hoc analysis from CARDEA showed 62.7% relative mortality reduction for Auxora vs. placebo in AKI subset.","End-of-Phase 2 meeting with FDA for AP/SIRS planned mid-2025; credit facility with Avenue Capital ($32.5M total)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173975,"accession_number":"0000950170-25-045729","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica reports FY2024 net loss $13.7M; cash $18.7M, funding into mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.7M in 2024 (vs $34.4M in 2023); R&D $14.5M, G&A $9.7M.","Cash $18.7M at Dec 31, 2024; plus $9.7M net from March 2025 debt facility; runway into mid-2026.","Phase 2 KOURAGE trial in AKI enrolling; data expected around end of 2025.","Post-hoc CARDEA analysis: 62.7% relative mortality reduction in AKI patients at day 30.","End-of-Phase 2 FDA meeting for acute pancreatitis program planned for mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173974,"accession_number":"0001193125-25-046225","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"CalciMedica secures up to $32.5M credit facility; $10M funded at close extends cash runway into mid-2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan agreement with Avenue Venture Opportunities Fund II provides up to $32.5M; initial tranche $10M funded Feb 28, 2025.","Additional tranches of $7.5M and $15M available upon achieving clinical milestones and mutual agreement.","Interest rate: prime + 5% (floor 12.75%); interest-only for 18 months; maturity Sept 1, 2028.","Warrant issued for 641,163 shares at $2.32 per share; exercisable until Feb 28, 2030.","No financial covenants; no minimum cash requirement; up to $2M principal convertible at 120% of stock purchase price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173973,"accession_number":"0001193125-25-044830","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CalciMedica reports 62.7% relative mortality reduction with Auxora in AKI subset of CARDEA trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In patients with AKI (eGFR ≤60) plus respiratory failure, Auxora reduced day-30 mortality by 62.7% vs placebo; 17.4% vs 46.7% died.","Absolute mortality reduction of 29.3% in AKI subset; full study showed 56.3% relative reduction (p=0.017) with 9.9% absolute reduction.","Preclinical and biomarker data supporting CRAC channel inhibition in AKI were also presented.","Ongoing Phase 2 KOURAGE trial in Stage 2/3 AKI with hypoxemic respiratory failure is expected to read out in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173972,"accession_number":"0001193125-25-005654","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CalciMedica director Eric Bjerkholt resigns; Alan Glicklich appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Bjerkholt resigned as director and audit committee chair effective Jan 15, 2025; no disagreement with company.","Board appointed Alan Glicklich, M.D. as Class I director effective same date, term expires at 2027 annual meeting.","Dr. Glicklich receives $40,000 annual cash retainer (pro-rated) and option for 20,000 shares vesting over three years.","No arrangements or transactions requiring disclosure under Item 404(a) between Dr. Glicklich and company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190946,"accession_number":"0001193125-24-283105","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CalciMedica resumes ATM offering for up to $4.45M after suspension","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Suspended ATM sales on Oct 30, 2024; resumed Dec 20 with new prospectus supplement.","Aggregate gross sales price of up to $4,450,000 of common stock under Offering Agreement with H.C. Wainwright & Co.","Legal opinion from Cooley LLP on share legality filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190945,"accession_number":"0000950170-24-125933","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica reports Q3 net loss $5.6M, completes $10.2M offering; cash runway into H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 net loss $5.6M ($0.50/sh); total loss from operations $5.7M.","Cash $14.6M at Sep 30; pro forma after Oct offering ~$23.7M, funds ops into H1 2026.","Completed Nov 1 public offering: 2.72M shares at $3.75, gross proceeds $10.2M.","Phase 2b CARPO: win ratio 1.64 (p=0.0372) for high-dose Auxora vs placebo; 100% relative risk reduction in new-onset severe respiratory failure.","Expects Phase 3 start in 2025; topline data from KOURAGE (AKI) and CRSPA (AIPT) trials in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190944,"accession_number":"0001193125-24-253754","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CalciMedica appoints Stephen Bardin as CFO; Dan Geffken resigns as interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dan Geffken resigned as interim CFO effective after filing Q3 2024 10-Q.","Stephen Bardin appointed CFO, principal financial and accounting officer; previously a consultant since April 2024.","Bardin served as CFO of ATAI Life Sciences (2022-2024) and SVP Finance at BridgeBio (2022).","Compensation: $380k base salary, $20k signing bonus, 100k stock option and 40k RSUs granted.","Option vests 25% on Oct 1, 2025 then monthly; RSUs vest 25% on Oct 1, 2025 then quarterly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190943,"accession_number":"0001193125-24-248761","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CalciMedica prices public offering of 2.72M shares at $3.75, raising $10.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 2,720,000 shares at $3.75/share for gross proceeds of $10.2M.","Underwriter granted 30-day option to purchase up to 408,000 additional shares.","Offering expected to close November 1, 2024, subject to customary conditions.","JonesTrading acting as sole book-running manager for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190942,"accession_number":"0001193125-24-247643","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"CalciMedica announces proposed public offering of common stock; preliminary cash $14.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Launched underwritten public offering of common stock; all shares sold by the company; no terms disclosed.","Preliminary cash $14.6M as of Sept 30, 2024 (unaudited); expects Q3 10-Q filing around Nov 14.","Suspended ATM sales agreement with H.C. Wainwright during the offering; JonesTrading sole book-runner.","Underwriter granted 30-day option to purchase up to additional 15% of shares sold in offering.","Offering subject to market conditions; no assurance as to completion, size, or terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190941,"accession_number":"0001193125-24-247004","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CalciMedica reports positive Phase 2b CARPO data: 100% reduction in severe respiratory failure with high-dose Auxora","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% relative risk reduction (p=0.0027) in new-onset severe respiratory failure for combined high/medium dose vs low dose/placebo.","Stratified win ratio of 1.640 (p=0.0372) for high dose (2.0 mg/kg) Auxora vs placebo across key endpoints.","No drug-related serious adverse events or deaths at high dose; trend of decreasing TESAE rates with higher dose.","Planning end-of-Phase 2 meeting with FDA to design Phase 3 trial of Auxora in acute pancreatitis with SIRS.","Median time to medically indicated discharge reduced by 15 hours for high dose vs placebo (89 vs 104 hours)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207431,"accession_number":"0001193125-24-207754","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-08-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"CalciMedica shareholders approve 1.5M share increase to equity plan; re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2023 Equity Incentive Plan, increasing authorized shares by 1,500,000.","Eric Bjerkholt and Fred Middleton re-elected as Class I directors for three-year terms.","Ratified appointment of Moss Adams LLP as independent auditor for fiscal year 2024.","Record date June 28, 2024; 10,750,156 shares outstanding entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207430,"accession_number":"0000950170-24-095450","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica reports Q2 net loss $4.0M; cash $19.1M; positive CARPO topline data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 2024 net loss $4.0M ($0.36/share) vs $3.8M for six months; operating loss $6.5M in Q2.","Cash, equivalents and short-term investments $19.1M as of June 30, 2024; runway into H2 2025.","Phase 2b CARPO trial for Auxora in acute pancreatitis met primary objective with statistically significant dose response.","First patient dosed in Phase 2 KOURAGE trial for severe AKI; topline data expected in 2025.","Company added to Russell Microcap Index effective July 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224851,"accession_number":"0001193125-24-169805","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CalciMedica announces positive Phase 2b CARPO topline data for Auxora in acute pancreatitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial enrolled 216 patients; primary endpoint met with up to 43.6% relative risk reduction in time to solid food tolerance vs placebo in hyper-inflamed subgroup.","Auxora showed statistically significant dose response: severe organ failure reduced by up to 61.7% in medium dose vs placebo.","High dose patients had 0% hospital stays >21 days vs 5.7% placebo; combined high/medium dose showed 84.3% relative risk reduction.","Auxora well-tolerated: only 1 drug-related treatment-emergent serious adverse event across all dose groups; no related deaths in high dose.","Company plans End-of-Phase 2 meeting with FDA and intends to present additional CT data at a medical meeting later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224850,"accession_number":"0000950170-24-058730","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica Q1 net income $0.1M; CARPO Phase 2b enrollment completed; cash into 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $0.1M ($0.01/share) driven by $5.6M non-cash gain on warrant liability, offsetting $5.8M operating loss.","Cash & equivalents $25.7M as of March 31, 2024; expected to fund operations into second half of 2025.","Phase 2b CARPO trial (Auxora in acute pancreatitis) fully enrolled at 216 patients; topline data expected in Q2 2024.","Phase 2 KOURAGE trial (Auxora in severe AKI with respiratory failure) cleared by FDA; first patient enrollment expected Q2 2024.","Private placement raised up to ~$54M ($20.4M upfront, ~$33.1M warrants) to support ongoing and planned trials."],"consensus_eps_estimate":null,"consensus_eps_actual":0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224849,"accession_number":"0001193125-24-092036","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"CalciMedica dismisses EY as auditor, engages Moss Adams; cites material weakness in internal controls","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Dismissed Ernst & Young LLP on April 5, 2024; engaged Moss Adams LLP on April 9, 2024 for FY2024 audit.","EY's reports for fiscal years 2022 and 2023 were unqualified; no disagreements on accounting principles.","Material weakness reported in internal controls over valuation of convertible promissory notes and warrant liabilities.","Moss Adams was not consulted on any accounting or auditing matters prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244120,"accession_number":"0001193125-24-081584","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CalciMedica increases ATM offering capacity from $4.7M to $17.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased maximum aggregate offering price under ATM agreement with H.C. Wainwright to $17,068,386.","Previous maximum was $4,700,000; prior sales totaled $279,771.74 under the agreement.","Filed prospectus supplement for the new $17,068,386 in common stock.","Legal opinion from Cooley LLP on share legality filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244119,"accession_number":"0000950170-24-037609","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica reports FY2023 net loss $34.4M; cash $11.2M; CARPO topline data Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and short-term investments $11.2M at Dec 31, 2023; pro forma after Jan 2024 private placement ~$25.5M, funding into 2H2025.","Net loss $34.4M ($7.66 per share) for FY2023; total operating expenses $38.1M including $16.2M one-time charges from reverse merger.","CARPO Phase 2b trial of Auxora in acute pancreatitis enrollment on track; topline data expected Q2 2024.","KOURAGE Phase 2 trial for severe AKI with AHRF cleared by FDA; first patient enrollment Q2 2024, data expected 2025.","CRSPA Phase 1/2 trial for asparaginase-induced pancreatic toxicity expanded to Phase 2; initial cohort data showed fewer hospital days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244118,"accession_number":"0001193125-24-033981","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA clears CalciMedica IND for Auxora Phase 2 KOURAGE trial in severe AKI with AHRF","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for KOURAGE Phase 2 trial of Auxora in stage 2/3 AKI with AHRF; enrollment starts H1 2024, data expected 2025.","Primary endpoint: days alive, ventilator- and dialysis-free through day 30. Secondary: MAKE-90 composite at 90 days.","Phase 2b CARPO trial in acute pancreatitis+SIRS data due H1 2024; Phase 1/2 CRSPA trial in pediatric AIPT data due H2 2024.","Plans to submit IND for oral candidate CM6336 for chronic pancreatitis and rheumatoid arthritis in H2 2024.","Cash runway into H2 2025 after private placement; multiple pipeline readouts ahead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244116,"accession_number":"0001193125-24-013513","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K/A","filed_at":"2024-01-24T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"CalciMedica corrects private placement terms; raises up to ~$55M for clinical trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected offering: 4,985,610 shares, 306,506 pre-funded warrants, 5,292,116 common warrants at $3.827/unit.","Upfront gross proceeds $20.4M; potential $33.1M from warrant exercise for total ~$54M (press release: ~$55M).","Preliminary cash Dec 31, 2023: $11.2M; net proceeds to fund Phase 2 trials of Auxora in AP and AKI.","New investors include Deerfield affiliate, Soleus Capital, Stonepine, Aisling; existing Sanderling and Bering participated.","Tranche A warrants ($5.36) expire Dec 31, 2024 or 30 days after AP topline; Tranche B ($7.15) expire Dec 31, 2026 or after AKI topline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244117,"accession_number":"0001193125-24-011738","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"CalciMedica raises up to $55M in private placement; $20.4M upfront from new and existing investors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront gross proceeds $20.4M from sale of 5.1M shares and pre-funded warrants to purchase 351,352 shares at $3.70/share.","Additional up to ~$34.2M possible if Tranche A ($5.36/share) and Tranche B ($7.15/share) warrants are exercised in cash.","Tranche A warrants expire earlier of 30 days after topline AP data or Dec 31, 2024; Tranche B earlier of 30 days after AKI data or Dec 31, 2026.","Cash, equivalents and short-term investments were $11.2M as of Dec 31, 2023 (preliminary); proceeds expected to fund Phase 2 trials in AP and AKI.","New investors include Deerfield Management, Soleus Capital, Stonepine Capital, Aisling Capital; JonesTrading as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261533,"accession_number":"0000950170-23-061514","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica Q3 net loss $4.6M; Auxora reduces hospital days 53% in AIPT trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.6M ($0.82/share) for Q3; cash $14.6M expected to fund through Q3 2024.","Auxora Phase 1/2 CRSPA in AIPT: 53% reduction in hospital days, 40% ICU days, eliminated TPN vs 27 days historical control. Data at ASH Dec 2023.","Phase 2b CARPO in acute pancreatitis with SIRS enrolling internationally; topline data H1 2024.","Preparing IND for Auxora in acute kidney injury; Phase 2 could start H1 2024 subject to funding.","Operating expenses $4.8M Q3; nine-month net loss $30.2M includes one-time merger charges."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261532,"accession_number":"0001193125-23-268948","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"CalciMedica reports $14.6M cash; Auxora shows 53% hospital stay reduction in CRSPA cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, and short-term investments of $14.6M as of Sept 30, 2023; expected to fund operations through Q3 2024.","Auxora (zegocractin) reduced average hospital stay from 13.4 to 6.3 days (53% reduction) in initial cohort of CRSPA study vs historical control.","No patients treated with Auxora required total parenteral nutrition (TPN) vs 68.8% in control.","Recommended dose established for children with ALL experiencing asparaginase-associated pancreatitis: dose level 1.","Data to be presented at ASH Meeting Dec 9-12, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278749,"accession_number":"0001193125-23-210794","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CalciMedica updates biz description with CARPO trial expansion, AKI plans, recasted financials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CARPO Phase 2b in AP+SIRS expanded to India; topline results expected first half 2024.","CRSPA Phase 1/2 in pediatric AIPT completed first cohort; data publication expected Q4 2023.","AKI plan: IND submission H2 2023; Phase 2 trial H1 2024 subject to additional funding.","CARDEA trial showed 56% relative mortality reduction at 30 days (p=0.0165) in severe COVID-19 pneumonia.","Audited recasted financial statements of Private CalciMedica as of Dec 31, 2022 and 2021 filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278748,"accession_number":"0001193125-23-209160","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","5.07","9.01"],"status":"ready","headline":"CalciMedica Q2 net loss $6.3M, cash $19.1M; Auxora Phase 2b expands to India, AKI IND expected by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.3M ($1.11/sh) in Q2 2023; cash $19.1M expected to fund operations for at least 12 months.","CARPO Phase 2b trial of Auxora in acute pancreatitis with SIRS expanded to India; enrollment complete expected Q1 2024, topline data H1 2024.","IND filing for Auxora in acute kidney injury expected by year-end 2023; trials could begin H1 2024 pending additional funding.","Appointed Raven Jaeger as Chief Regulatory Officer and Andrew Cunningham as SVP Clinical Development; stock relisted on Nasdaq in June.","Preclinical data in JCI Insight show Orai1 inhibition prevents progression of recurrent acute pancreatitis and early chronic pancreatitis."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296991,"accession_number":"0001193125-23-176143","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"CalciMedica sets 2023 annual meeting Aug 9; proposal deadline July 7","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting set for August 9, 2023; record date June 23, 2023.","Stockholder proposals for inclusion in proxy due by July 7, 2023 at 5:00 PM ET.","Universal proxy rule notices for director nominations must comply with Rule 14a-19.","Proposals must be mailed to CalciMedica at 505 Coast Blvd S, Suite 307, La Jolla, CA 92307."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296990,"accession_number":"0001193125-23-167330","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CalciMedica posts updated corporate presentation; no specific new data disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted an updated corporate presentation on the 'Investors and Media' section of its website.","Presentation titled 'Developing First-in-Class Therapies for Acute Inflammatory Diseases with High Unmet Need' is dated June 2023.","No financial results, pipeline milestones, or other quantifiable updates are provided in the attached exhibit.","Presentation may be used in discussions with analysts and investors; content is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296989,"accession_number":"0001193125-23-165409","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CalciMedica receives Nasdaq approval, relisting starts June 14, 2023 under CALC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq approved relisting on Capital Market; trading begins June 14, 2023.","Common stock to trade under ticker 'CALC' on Nasdaq after OTCQB trading.","CEO cites improved liquidity, broader investor access, and support for clinical strategy.","Company continues Phase 2 trials of Auxora for inflammatory diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296988,"accession_number":"0001193125-23-144226","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CalciMedica Q1 net loss $19.3M ($23.43/sh); cash $34.2M; Nasdaq delisted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.3M ($23.43 diluted EPS); operating expenses $22.3M incl. $16.2M one-time Graybug merger costs.","Cash, equivalents and short-term investments $34.2M as of March 31; expects runway into H2 2024.","CARPO Phase 2b trial: IDMC reviewed first 90 pts, recommended continue; expects topline Q1 2024.","Stock suspended from Nasdaq March 30; now trading on OTCQB, working to relist.","Merger with Graybug closed March 20; CalciMedica equityholders own ~72%, Graybug ~28%."],"consensus_eps_estimate":null,"consensus_eps_actual":-23.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296987,"accession_number":"0001193125-23-143456","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"CalciMedica restates FY2022 financials due to errors in convertible note and warrant valuation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board concluded Dec 31, 2022 financial statements should no longer be relied upon.","Errors in valuation of convertible promissory notes and warrant liability; models did not consider merger conversion formula.","Restatement expected to decrease carrying value of notes and warrant liability, reduce net loss and net loss per share.","Company plans to file an amended report to reflect corrections; subject to completion of Ernst & Young audit.","Previously furnished/filed reports describing financial results from Original Report should no longer be relied upon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296985,"accession_number":"0001193125-23-143469","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K/A","filed_at":"2023-05-12T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"CalciMedica restates FY2022 results; net loss cut $6.7M on valuation errors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board concluded on May 8, 2023 that FY2022 financials contained errors in convertible note and warrant liability valuations.","Restatement reduced net loss and comprehensive loss from $14.5M to $7.8M; EPS improved from ($5.08) to ($3.20).","Warrant liability restated to $2.6M (from $4.2M); convertible promissory notes restated to $5.2M (from $8.9M).","Prior FY2022 financials and related communications should no longer be relied upon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296986,"accession_number":"0001193125-23-137097","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"CalciMedica delisted from Nasdaq, now trading on OTCQB after failing initial listing requirements","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq delisting notice on March 21, 2023 for not meeting initial listing requirements after merger.","Trading suspended March 31, 2023, moved to Pink sheets April 3, 2023.","Upgraded to OTCQB tier on April 26, 2023, providing Real Time Level 2 quotes.","Withdrew Nasdaq appeal on May 1, 2023; Nasdaq to file Form 25 delisting notice.","Company maintains initial listing application on Nasdaq and intends to seek relisting on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":296984,"accession_number":"0001193125-23-090853","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K/A","filed_at":"2023-04-04T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"CalciMedica files audited FY2022 financials post-reverse merger; net loss $14.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $14.5M in 2022, accumulated deficit $118.4M as of Dec 31, 2022.","Cash and cash equivalents $1.3M at year-end 2022; merger and private placement raised ~$34.2M in March 2023.","Reverse merger closed March 20, 2023; Graybug Vision renamed CalciMedica, surviving as public entity.","Former CalciMedica stockholders own ~72% of combined company on fully diluted basis.","Going concern opinion included; management expects new funds to support operations beyond 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317367,"accession_number":"0001193125-23-076714","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.01","3.01","9.01","3.02","3.03","5.01","5.02","5.03","8.01"],"status":"ready","headline":"CalciMedica closes reverse merger with Graybug; Nasdaq delisting notice received for failing initial listing criteria","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed March 20, 2023; 3.95M shares issued to CalciMedica stockholders; CalciMedica equityholders own ~72% of combined company.","Company renamed CalciMedica, Inc.; ticker changes to CALC on March 21, 2023, but Nasdaq staff determined it fails initial listing requirements.","Nasdaq suspension scheduled for March 30; Company will appeal and intends to trade on OTCQB if unsuccessful.","New board and executive team from CalciMedica: CEO A. Rachel Leheny, COO Michael Dunn, CFO Daniel Geffken; prior Graybug CEO and CFO terminated.","Pre-merger private placement raised $10.3M from ~20.7M shares of CalciMedica common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317371,"accession_number":"0001193125-23-071452","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-03-15T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Graybug stockholders approve merger with CalciMedica; 14-to-1 reverse split effective Mar 17","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five proposals approved: share issuance (13.2M for), charter amendment, equity plan, ESPP, and adjournment.","Reverse stock split ratio set at 14-to-1, effective after market close March 17, 2023.","Outstanding shares will reduce from ~22M to ~1.57M; no fractional shares—cash in lieu.","Common stock to trade split-adjusted on Nasdaq under new CUSIP 38942Q 202 starting March 20.","Merger with CalciMedica remains subject to customary closing conditions; no closing date announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317370,"accession_number":"0001193125-23-059999","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Graybug Vision discloses supplemental merger details, CMO Parisa Zamiri terminated ahead of CalciMedica merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CMO Parisa Zamiri terminated Feb 28, 2023; receives $829,084 severance, COBRA, and stock acceleration.","Zamiri also signed consulting agreement at $350/hr up to 8 hrs/week through May 21, 2023.","Supplemental disclosures include corrected CalciMedica financial projections (revenue starting FY2028) and Piper Sandler analysis.","Piper Sandler to receive $3M fee for merger advisory; $100K retainer and $750K opinion fee already earned.","Four stockholder lawsuits and nine demand letters allege proxy statement omissions; Graybug believes claims without merit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317369,"accession_number":"0001193125-23-041092","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Graybug Vision enters $2M bridge loan with CalciMedica and amends merger terms","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Graybug agrees to lend CalciMedica up to $2M at 7.5% annual interest; initial $500K advanced.","Amendment ensures outstanding loan principal and interest included in Graybug's net cash for merger closing.","CalciMedica must use proceeds for payroll, rent, clinical trial, and regulatory costs; additional draws require Graybug approval.","Merger termination triggers mandatory prepayment or credit against termination fees; three-month maturity after anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317368,"accession_number":"0001193125-23-030003","cik":1534133,"company_name":"CalciMedica, Inc.","ticker":"CALC","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Graybug Vision appoints five new directors contingent on CalciMedica merger closing","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["New directors: A. Rachel Leheny, Eric W. Roberts, Robert N. Wilson, Fred Middleton, Allan Shaw, effective at merger close.","Resigning directors: Christy Shaffer, Christina Ackermann, Julie Eastland, Dirk Sauer, effective at merger close.","Eric Bjerkholt resigns as Class II director, reappointed as Class I director, effective at merger close.","Robert N. Wilson appointed Chair of the Board; committee chairs assigned to Bjerkholt (Audit), Shaw (Compensation), Wilson (Governance).","Changes are contingent upon closing of the previously announced merger with CalciMedica, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12164483.99140478,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-09T23:59:59+00:00|317368"}